The landscape of the global pharmaceutical industry in Fiscal Year 2025 (FY2025) has been defined by a striking paradox: while the broader clinical development pipeline experienced a contraction, the industry’s top-selling specialty franchises demonstrated unprecedented resilience and compounding growth. As the industry settles into a post-pandemic era, the "Pharma 50" leaderboard—an analysis of the top-selling drugs by revenue—reveals a significant shift in therapeutic priorities, led by the meteoric rise of metabolic health treatments and the continued dominance of immunology blockbusters.
Main Facts: The Battle for Supremacy
The defining narrative of FY2025 remains the tension at the top of the revenue charts. While Merck’s oncology titan, Keytruda, successfully defended its position as the world’s No. 1 brand with a formidable $31.68 billion in sales, the underlying momentum has shifted elsewhere.
At the molecule level, the combined forces of Eli Lilly’s tirzepatide (marketed as Mounjaro and Zepbound) and Novo Nordisk’s semaglutide (marketed as Ozempic and Wegovy) have fundamentally reshaped the hierarchy. The demand for GLP-1 receptor agonists has reached a scale previously unseen in the history of pharmaceutical commercialization. Mounjaro, in particular, witnessed an explosive 99% year-over-year growth, cementing its status as a cornerstone of the modern metabolic portfolio.
Beyond the weight-loss and diabetes giants, the industry’s "specialty" core is thriving. Franchises such as Skyrizi, Rinvoq, Dupixent, Darzalex, Tremfya, and Kisqali all recorded significant double-digit growth. Notably, the immunology sector remains the industry’s most robust engine, expanding by 20.6% even as other areas of the market face the inevitable "patent cliff" and the expiration of legacy blockbusters.
Chronology: A Year of Seismic Shifts
The trajectory of FY2025 was marked by distinct phases of market reaction and therapeutic adoption:
- Q1 2025: The Metabolic Acceleration: The year began with a continued surge in demand for GLP-1s, forcing manufacturers to scramble for manufacturing capacity. Lilly’s Zepbound, specifically, signaled that the market for obesity treatments was far from saturation.
- Q2 2025: The Immunology Consolidation: As Humira (AbbVie) continued its decline—posting a 49.5% drop due to biosimilar competition—the market saw the successful rotation of patients toward newer, more targeted agents like Skyrizi and Rinvoq. This confirmed that the "Humira cliff" was not a systemic failure of immunology, but a natural evolution of the standard of care.
- Q3 2025: The Oncology Rebound: Despite the noise surrounding metabolic health, established oncology powerhouses like Darzalex (J&J) and Opdivo (BMS) proved that cancer therapeutics remain a stable, high-value segment of the industry.
- Q4 2025: The Normalization of COVID-19 Revenue: By the end of the year, the impact of COVID-19 therapeutics, such as Pfizer’s Comirnaty and Paxlovid, continued to recede from the revenue peaks of 2021–2022. This forced companies like Pfizer to pivot their capital allocation toward cardiovascular and oncology acquisitions, such as their focus on the Vyndaqel family.
Supporting Data: The Anatomy of the Top 10
The following table extracts the core data from the FY2025 Pharma 50 analysis, illustrating the disparity between legacy assets and high-growth innovators.
| Rank | Drug | Manufacturer | FY2025 ($M) | YoY% Change |
|---|---|---|---|---|
| 1 | Keytruda | Merck | 31,680 | 7.5% |
| 2 | Mounjaro | Eli Lilly | 22,965 | 99.0% |
| 3 | Ozempic | Novo Nordisk | 19,206 | 5.6% |
| 4 | Dupixent | Sanofi/Regeneron | 17,736 | 20.2% |
| 5 | Skyrizi | AbbVie | 17,562 | 49.9% |
| 6 | Eliquis | BMS/Pfizer | 14,443 | 8.3% |
| 7 | Darzalex | J&J | 14,351 | 23.0% |
| 8 | Biktarvy | Gilead Sciences | 14,300 | 6.7% |
| 9 | Zepbound | Eli Lilly | 13,542 | 174.9% |
| 10 | Wegovy | Novo Nordisk | 11,955 | 35.9% |
The data underscores a vital trend: companies with deep pipelines in chronic inflammatory diseases and metabolic health are currently dominating the top 20. Drugs like Stelara (-41.3%) and Revlimid (-48.9%) serve as cautionary tales of what happens when exclusivity expires, whereas the rise of Kisqali (57.7%) and Breyanzi (81.8%) demonstrates the value of innovation in oncology and hematology.
Official Responses and Strategic Perspectives
Industry leaders have largely adopted a "portfolio diversification" strategy in response to these figures. During recent earnings calls, executives from companies like AbbVie and J&J emphasized that the revenue decline of legacy assets like Humira and Stelara was long anticipated and factored into long-term growth projections.
"The transition from legacy biologicals to the next generation of targeted therapies is not just a trend—it is a transformation of the patient experience," noted one industry analyst. Companies are effectively using the cash flows generated by the "old guard" to fund the commercialization of new, high-growth assets.
Furthermore, Eli Lilly and Novo Nordisk have consistently cited the "supply-constrained environment" as the primary barrier to even higher revenue numbers. Their official stance has been one of aggressive infrastructure investment, with billions of dollars being poured into global manufacturing sites to ensure that the production of tirzepatide and semaglutide can eventually meet the immense global patient demand.
Implications: Where the Industry Goes from Here
The FY2025 data serves as a roadmap for the future of drug discovery and commercialization. Several key implications emerge:
1. The Death of the "One-Size-Fits-All" Blockbuster
The era of the "universal" drug is waning. Even as Keytruda maintains its top spot, it is increasingly being used in highly specific, biomarker-driven combinations. The market is rewarding drugs that offer precision, whether that is in the immunology space (Skyrizi) or in metabolic management.
2. The Resilience of Specialty Franchises
Specialty medicines—drugs that treat complex, chronic, or rare conditions—are now the bedrock of pharma revenue. Investors are signaling a clear preference for companies that can build a "franchise" around a molecule, utilizing it across multiple indications (such as Dupixent’s expansion from eczema to asthma and beyond).
3. The Pivot from Pandemic-Driven Revenue
The rapid decline of COVID-19-related revenues (Paxlovid’s -58.7%) has accelerated the industry’s need to find "long-tail" revenue. We are seeing a move away from transient infectious disease solutions back toward the stable, long-term growth of cardiovascular health, immunology, and oncology.
4. Currency Volatility and Global Reporting
A notable aspect of the FY2025 report is the divergence in reporting currencies. With major players like Novo Nordisk (DKK), Sanofi (EUR), and GSK (GBP) facing fluctuating exchange rates against the US Dollar, the IRS conversion rates used in this analysis highlight the importance of understanding the "real-world" value of these drugs independent of currency headwinds.
5. The Pipeline Contraction
Perhaps the most concerning takeaway from the FY2025 analysis is the overall contraction of the industry pipeline. While the top 50 drugs are performing well, the total number of assets in early-stage development has dipped. This suggests that while pharma is currently profitable, the industry must address the underlying sustainability of its innovation engine to prevent a long-term deficit of new therapies.
Conclusion
The FY2025 Pharma 50 report paints a picture of an industry at a crossroads. It is an industry that has successfully leveraged the massive demand for weight-loss and diabetes treatments to reach new financial heights, while simultaneously navigating the difficult transition away from the pandemic-era business model.
As we look toward FY2026 and beyond, the focus will likely shift from the sheer volume of sales to the sustainability of these growth rates. With biosimilars looming over many of the drugs currently in the top 20, the race is on for the next generation of "specialty franchises." For now, the incumbents remain strong, but the data clearly shows that in the modern pharmaceutical market, staying at the top requires constant innovation, massive manufacturing scale, and a deep understanding of patient needs in an increasingly competitive, data-driven environment.
The industry remains a powerhouse, but it is one that is fundamentally changing—moving away from the broad-spectrum blockbusters of the past and toward the high-precision, high-impact therapeutics of the future.
About the Author
